INTRODUCTION
Epinephrine and glucagon exhibit similar pharmacologic effects in the adult rat heart, positive chronotropic and inotropic effects and glycogenolysis (1) (2) (3) . These effects appear to be secondary to the stimulation of adenylate cyclase with the consequent increase in intracellular concentration of cyclic adenosine 3',5'-monophosphate (cyThis paper was presented in part before the Annual National Meeting of the American Federation for Clinical Research, Atlantic City, N. J. 30 April 1972. Received for publication 17 May 1972 and in revised form 1 August 1972. clic AMP). Evidence supporting the role of cyclic AMP in the action of these hormones has recently been reviewed (4) . There is evidence that whereas the same adenylate cyclase system in myocardial tissue is activated by epinephrine and glucagon, the receptors for the two hormones are different (5, 6) . Thus, beta adrenergic blockade inhibits activation of myocardial adenylate cyclase by epinephrine but not by glucagon. In the course of studies concerned with the regulation of glycogen metabolism in the developing fetal rat heart, it was noted that epinephrine and dibutyryl cyclic AMP but not glucagon produced glycogenolysis. This observation suggested that the glucagon receptor was not operative in the fetal rat heart. In the present communication evidence is presented that adenylate cyclase activity and activation by epinephrine occur early in the course of fetal development but that activation by glucagon does not appear until several weeks after birth. For comparison, studies of hormonal activation of adenylate cyclase and hormone-induced depletion of glycogen in liver are also described.
METHODS
Animals. Pregnant rats of known gestational age were obtained from the Charles River Breeding Laboratories, Inc., Wilmington, Mass. and maintained on Purina Rat Chow. Gestational age of the fetuses was confirmed by their weight (7) .
In vivo glycogenolysis. Neonatal rats, 48 h or less in age, were injected intraperitoneally with 0.1 ml of 0.9% sodium chloride alone or with 6 lxg of glucagon, 10 ,g of epinephrine or 2.5 mg of dibutyryl cyclic AMP. At specified time intervals the animals were decapitated, and blood was collected in pour plates containing a small amount of powered heparin. The hearts and livers were then excised, frozen on dry ice, weighed, and analyzed for glycogen as described below. The heparinized blood was centrifuged, and All rats were born on the same date and studied in a single experiment less than 24 h after birth. The animals were sacrificed 2 h after injection. The P values (given in parenthesis) are compared to the saline-injected animals.
The mean ±SEM are presented. N is the number of observations. a 50 lambda sample of plasma was analyzed for glucose as described below. Analyses. The hearts and livers were digested in a solution of hot 30%o KOH and 0.5% Na2SO4, and glycogen was isolated by the method of Good, Kramer, and Somogyi (8) . The ]. In each experiment three blanks using boiled homogenate were carried through the entire incubation and isolation procedure. "4C counts from these blanks ranged from 10 to 40 cpm above background. The mean value for the blanks in all experiments was 30% of the control value and ranged from 13 to 60%. The mean The time-course for each substance was determined on animals born on the same day in a single experiment. The neonates were studied within 48 h of birth. Results are expressed as mM. N is the number of observations. The mean ±SEM are presented. The numbers in parenthesis are P values as compared to zero time. RESULTS Effects of epinephrine, glucagon, and dibutyryl cyclic AMP on plasma glucose. At 2 h both epinephrine and glucagon significantly increased plasma glucose above the saline-injected control, whereas dibutyryl cyclic AMP did not (Table I ). The effects of the injection of these substances on plasma glucose as a function of time are summarized in Table II . The plasma glucose had fallen significantly by 60 min in the saline-injected controls. It subsequently returned toward basal values. Dibutyryl cyclic AMP, glucagon, and epinephrine each caused a significant increase in plasma glucose by 30 min. The increase caused by dibutyryl cyclic AMP was quantitatively the smallest and was no longer significant by 60 min and thereafter (Table II) . Epinephrine caused quantitatively the greatest increase in plasma glucose, and glucagon was intermediate in its effect.
Effects of epinephrine, glucagon, and dibutyryl cyclic AMP on glycogenolysis. Glycogen content of both heart and liver vary widely during the neonatal period (12, 13) . In order to minimize the effects of these changes in basal glycogen content, two types of experiments were performed. In one series of experiments all Table I . At 2 h, dibutyryl cyclic AMP, epinephrine, and glucagon each lowered hepatic glycogen significantly as compared to the saline-injected controls. Whereas dibutyryl cyclic AMP and epinephrine also caused significant mean decreases in myocardial glycogen content, glucagon did not (Table I ).
In the second series of experiments, the time-course of myocardial and hepatic glycogen after injection was studied. In this series of experiments, the animals in each treatment group were studied on the lame day.
Representative experiments are summarized in Tables  III and IV of dibutyryl cyclic AMP or 10 izg of epinephrine was followed by significant mean decreases in cardiac gly- cogen by 60 min (Table III) . In contrast, glucagon injection resulted in significant mean increases in myocardial glycogen content. This suggested unresponsiveness of myocardial adenylate cyclase to glucagon which in conjunction with mobilization of hepatic glycogen might result in increased myocardial glycogen. Each of the three substances caused hepatic glycogenolysis (Table IV) . Effects of epinephrine and glucagon on adenylate cyclase activity. Representative experiments summarizing the effects of glucagon and epinephrine on adenylate cyclase activity in fetal rat hearts on the 16th, 18th, and 21st days of a 22i day gestation are depicted in Table V and Fig. 1 . No stimulating effect of glucagon was detected. Epinephrine 10-mol/liter, stimulated adenylate cyclase at all ages; significant mean increases were seen at concentrations of 10' mol/liter and above.
However, both epinephrine and glucagon stimulated adenylate cyclase in heart tissue homogenates from weanling rats (Fig. 2) at concentrations of 10' mol/ liter and above. In Table VI Mean ±SEM are presented.
* As compared to control.
gon, 10-' mol/liter, was not present in neonatal tissue but had appeared by the 4th wk after birth. Adenylate icyclase activation by epinephrine was consistently greater than that produced by glucagon. In all studies in which the effects of NaF, 102 mol/liter, were examined, significant augmentation occurred (Tables V  and VI) . Hepatic adenylate cyclase activity in tissues from 16, 18 , and 20 day old fetal rats was significantly increased by epinephrine, 10-' mol/liter, glucagon, 10-' mol/liter, and NaF, 10-2 mol/liter (Table VII) .
DISCUSSION
Glucagon, epinephrine, and dibutyryl cyclic AMP given to the neonatal rat in vivo resulted in increased glycogenolysis in the liver, whereas epinephrine and dibutyryl cyclic AMP but not glucagon were effective in the heart. The opposing effects of epinephrine and glucagon Mean ASEM are presented.
on myocardial glycogen content could have resulted from pharmacologic effects of the hormones district from their effect on myocardial adenylate cyclase. If, for example, epinephrine inhibited while glucagon stimulated pancreatic insulin release in these animals as they do in vitro (14) , then the resultant insulin-induced myocardial glycogen synthesis (13) could have obscured the glycolytic effect of glucagon. This interpretation seems unlikely, however, since insulin release would also have been expected to obscure the effect of glucagon on hepatic glycogen. In addition, the dibutyryl cyclic AMP would also have been expected to cause insulin release (14) and should have had effects on myocardial glycogen similar to glucagon. This was not the case. A more likely explanation for these results is that the glycagon receptor on the adenylate cyclase enzyme system either had not developed or was inoperative in the neonatal rat heart, whereas the epinephrine receptor was already functional.
In vitro both epinephrine and glucagon stimulated adenylate cyclase activity in hearts from weanling and adult rats. Whereas the concentration at which glucagon stimulated adenylate cyclase in our studies is similar to that observed by Murad and Vaughn (3), the magnitude of increase in adenylate cyclase activity produced by glucagon is less. There are several differences between our studies and those of Murad and Vaughan which may explain these differences. Whereas we used a resuspended 600 X g pellet, they used a partially purified membrane preparation. It is possible that a specific inhibitor of glucagon activation of adenylate cyclase is present in the rat heart similar to that previously dehe number of livers per homogenate ranged from scribed in the rat liver (15) . In this case purification of the membrane would remove the inhibitor and, thus, increase the activation of adenylate cyclase by glucagon in the adult rat heart. We were reluctant to carry out purifications since liability of fetal myocardial glucagon receptor has been demonstrated in fetal tissues (16) . In these studies performed in the lamb, Friedman, Sobel, and Cooper (16) showed that partial purification of fetal myocardial membranes abolished activation of adenylate cyclase by glucagon. We therefore chose to manipulate the membranes minimally. Under the experimentally conditions described, epinephrine significantly increased myocardial adenylate cyclase activity in tissues from both fetal and neonatal animals, and epinephrine and glucagon each stimulated adenylate cyclase activity in hearts from weanling and adult rats.
In contrast, glucagon did not activate the adenylate cyclase in hearts from either fetal or neonatal rats.
The finding that in fetal rat heart both glycogenolysis and adenylate cyclase activity can be increased by epinephrine suggest that the epinephrine receptor is operative in this fetal tissue. The failure of glucagon to augment myocardial glycogenolysis in vivo and adenylate cyclase activity in vitro in the fetus and newborn suggests that the glucagon receptor is not operative in these tissues. These studies do not reveal the precise defects in the glucagon receptor in the fetal myocardium. Failure of the development of the receptor until after birth or the presence of an inhibitor are equally possible.
The results from fetal rat liver suggest that both glycogenolysis and adenylate cyclase activity can be increased by both epinephrine and by glucagon indicating that both receptors are operative in this fetal tissue. Augmentation of fetal hepatic adenylate cyclase by epinephrine and glucagon has been observed previously by other investigators (17, 18) . Previously it has been suggested that epinephrine and glucagon activate a single myocardial adenylate cyclase enzyme by interacting with separate receptors (4-6). The present results indicate that the glucagon receptor for adenylate cyclase in the rat does not become operative until after the appearance of the enzyme and beta adrenergic receptor. Also, it has been observed experimentally in cats that the ability of glucagon but not epinephrine to stimulate myocardial adenylate cyclase activity is lost during chronic heart failure (4). Thus, in addition to its developmental distinctiveness, the glucagon receptor may be altered or inactivated apparently without any changes in the enzyme or beta adrenergic receptor.
A final question raised by these studies is whether differential development of glucagon activation of adenylate cyclase serves a physiologically useful purpose. A definite physiologic role of glucagon on the myocardium is not presently substantiated. Most studies including the present one have utilized pharmacologic doses of glucagon to obtain myocardial effects. These results, however, have not established a physiologic role for glucagon on the myocardium. Mayer, Namm, and Rice (2) have observed effects on contractile amplitude in the isolated perfused rat heart at glucagon concentrations as low as 10-1'M which is in the physiologic range for the neonatal rats (19) . It also has been observed that there are unequivocal increases in plasma glucagon in the rat at birth (19) . These data suggest that glucagon could serve to mobilize hepatic glycogen stores in the neonatal period and, thus, to stabilize plasma glucose at birth.
Further studies to determine the physiologic role of glucagon in the neonatal period appear warranted.
